Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-11, Vol.30, p.ix160 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | ix160 |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Yoh, K. Atagi, S. Reck, M. Garon, E.B. Aix, S. Ponce Moro-Sibilot, D. Winfree, K.B. Frimodt-Moller, B. Zimmermann, A.H. Visseren-Grul, C.M. Nakagawa, K. |
| description | |
| doi_str_mv | 10.1093/annonc/mdz437.005 |
| format | Article |
| fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdz437_005</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_1093_annonc_mdz437_005</sourcerecordid><originalsourceid>FETCH-LOGICAL-c855-ee0667e01a5eacbb9d0c7580a1ad63a817c67d6caf995576bfcdbfcacdfd631c3</originalsourceid><addsrcrecordid>eNotkEFLw0AQhfegYK3-AG9zbNG0u02TNMdS0hoIWmIvnsJks8GVbDbsbgT9Yf4-08bDMPN4j3nwEfLA6ILR2F9i2-qWL1X1s_ajBaXBFZnQeOV7UeCvb8ittZ-U0jBexRPye0QnReu8WvPeigp077hWwoJsIU-y7fsTIHQfaAWkaQrOSGxA12BQ9VyaXmEJXdNbEKbRTrayhFmOKjHNHL6EsYPTNchFqcdYkmcwO5b6Ehg6-tYZgW5oTg773FO9uwglHNrhlBxe3nbZDmZn-xHURc3vyHWNjRX3_3tKTvvktHv2stdDuttmHt8EgScEDcNIUIaBQF6WcUV5FGwoMqxCHzcs4mFUhRzrOA6CKCxrXg2DvKoHn3F_Stj4lhttrRF10Rmp0HwXjBZn1sXIuhhZFwNr_w_H4Xi4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Yoh, K. ; Atagi, S. ; Reck, M. ; Garon, E.B. ; Aix, S. Ponce ; Moro-Sibilot, D. ; Winfree, K.B. ; Frimodt-Moller, B. ; Zimmermann, A.H. ; Visseren-Grul, C.M. ; Nakagawa, K.</creator><creatorcontrib>Yoh, K. ; Atagi, S. ; Reck, M. ; Garon, E.B. ; Aix, S. Ponce ; Moro-Sibilot, D. ; Winfree, K.B. ; Frimodt-Moller, B. ; Zimmermann, A.H. ; Visseren-Grul, C.M. ; Nakagawa, K.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>DOI: 10.1093/annonc/mdz437.005</identifier><language>eng</language><ispartof>Annals of oncology, 2019-11, Vol.30, p.ix160</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Yoh, K.</creatorcontrib><creatorcontrib>Atagi, S.</creatorcontrib><creatorcontrib>Reck, M.</creatorcontrib><creatorcontrib>Garon, E.B.</creatorcontrib><creatorcontrib>Aix, S. Ponce</creatorcontrib><creatorcontrib>Moro-Sibilot, D.</creatorcontrib><creatorcontrib>Winfree, K.B.</creatorcontrib><creatorcontrib>Frimodt-Moller, B.</creatorcontrib><creatorcontrib>Zimmermann, A.H.</creatorcontrib><creatorcontrib>Visseren-Grul, C.M.</creatorcontrib><creatorcontrib>Nakagawa, K.</creatorcontrib><title>Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)</title><title>Annals of oncology</title><issn>0923-7534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNotkEFLw0AQhfegYK3-AG9zbNG0u02TNMdS0hoIWmIvnsJks8GVbDbsbgT9Yf4-08bDMPN4j3nwEfLA6ILR2F9i2-qWL1X1s_ajBaXBFZnQeOV7UeCvb8ittZ-U0jBexRPye0QnReu8WvPeigp077hWwoJsIU-y7fsTIHQfaAWkaQrOSGxA12BQ9VyaXmEJXdNbEKbRTrayhFmOKjHNHL6EsYPTNchFqcdYkmcwO5b6Ehg6-tYZgW5oTg773FO9uwglHNrhlBxe3nbZDmZn-xHURc3vyHWNjRX3_3tKTvvktHv2stdDuttmHt8EgScEDcNIUIaBQF6WcUV5FGwoMqxCHzcs4mFUhRzrOA6CKCxrXg2DvKoHn3F_Stj4lhttrRF10Rmp0HwXjBZn1sXIuhhZFwNr_w_H4Xi4</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Yoh, K.</creator><creator>Atagi, S.</creator><creator>Reck, M.</creator><creator>Garon, E.B.</creator><creator>Aix, S. Ponce</creator><creator>Moro-Sibilot, D.</creator><creator>Winfree, K.B.</creator><creator>Frimodt-Moller, B.</creator><creator>Zimmermann, A.H.</creator><creator>Visseren-Grul, C.M.</creator><creator>Nakagawa, K.</creator><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201911</creationdate><title>Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)</title><author>Yoh, K. ; Atagi, S. ; Reck, M. ; Garon, E.B. ; Aix, S. Ponce ; Moro-Sibilot, D. ; Winfree, K.B. ; Frimodt-Moller, B. ; Zimmermann, A.H. ; Visseren-Grul, C.M. ; Nakagawa, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c855-ee0667e01a5eacbb9d0c7580a1ad63a817c67d6caf995576bfcdbfcacdfd631c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoh, K.</creatorcontrib><creatorcontrib>Atagi, S.</creatorcontrib><creatorcontrib>Reck, M.</creatorcontrib><creatorcontrib>Garon, E.B.</creatorcontrib><creatorcontrib>Aix, S. Ponce</creatorcontrib><creatorcontrib>Moro-Sibilot, D.</creatorcontrib><creatorcontrib>Winfree, K.B.</creatorcontrib><creatorcontrib>Frimodt-Moller, B.</creatorcontrib><creatorcontrib>Zimmermann, A.H.</creatorcontrib><creatorcontrib>Visseren-Grul, C.M.</creatorcontrib><creatorcontrib>Nakagawa, K.</creatorcontrib><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoh, K.</au><au>Atagi, S.</au><au>Reck, M.</au><au>Garon, E.B.</au><au>Aix, S. Ponce</au><au>Moro-Sibilot, D.</au><au>Winfree, K.B.</au><au>Frimodt-Moller, B.</au><au>Zimmermann, A.H.</au><au>Visseren-Grul, C.M.</au><au>Nakagawa, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC)</atitle><jtitle>Annals of oncology</jtitle><date>2019-11</date><risdate>2019</risdate><volume>30</volume><spage>ix160</spage><pages>ix160-</pages><issn>0923-7534</issn><doi>10.1093/annonc/mdz437.005</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-11, Vol.30, p.ix160 |
| issn | 0923-7534 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdz437_005 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Patient-focused outcomes in RELAY, a phase III trial of ramucirumab plus erlotinib (RamErl) versus placebo plus ERL (PboErl) in untreated EGFR-mutated metastatic NSCLC (EGFR+ mNSCLC) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T00%3A48%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Patient-focused%20outcomes%20in%20RELAY,%20a%20phase%20III%20trial%20of%20ramucirumab%20plus%20erlotinib%20(RamErl)%20versus%20placebo%20plus%20ERL%20(PboErl)%20in%20untreated%20EGFR-mutated%20metastatic%20NSCLC%20(EGFR+%20mNSCLC)&rft.jtitle=Annals%20of%20oncology&rft.au=Yoh,%20K.&rft.date=2019-11&rft.volume=30&rft.spage=ix160&rft.pages=ix160-&rft.issn=0923-7534&rft_id=info:doi/10.1093/annonc/mdz437.005&rft_dat=%3Ccrossref%3E10_1093_annonc_mdz437_005%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |